The history of Viagra presents a challenging picture for those considering investment. While the initial launch generated substantial gains, the lapse of its intellectual property protection opened the floodgates to generic versions, dramatically diminishing market share. This poses a unique challenge for pharmaceutical companies banking on related

The story of Viagra, and its parent company copyright, presents a challenging case study for investors. At first a blockbuster drug, producing billions in income, its intellectual property lapse created a deluge of knock-off medications, significantly impacting its dominance. While specific businesses may attempt to capitalize on male sexual dysfun